Transactions
64
Insider / Moderna, Inc.
Klinger Shannon Thyme
Chief Legal Officer at Moderna, Inc.
- Company
- Moderna, Inc.
- Ticker
- MRNA
- First filing on record
- December 1, 2025
- Latest trade on record
- September 4, 2026
- SEC filings
- EDGAR ↗
Klinger Shannon Thyme, Chief Legal Officer at Moderna, Inc., has disclosed 64 transactions in MRNA since December 1, 2025: 0 purchases (0 open-market buys) and 21 sales, worth about $4.7M at the reported prices. The latest was filed September 8, 2026, 4 days after the trade; 3 filings were late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
21
Avg. disclosure lag
2.8d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Klinger Shannon Thyme made no purchases and 21 sales worth $4.1M, plus 43 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Klinger Shannon Thyme has traded 1 stock on record; the largest by dollars is MRNA.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
1 of 12 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 40 | 242,556 | $645K |
| F | Shares withheld for tax | 18 | 49,911 | $2.7M |
| A | Grant or award | 3 | 70,458 | — |
| S | Open-market sale | 3 | 20,827 | $1.4M |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 52 | 0 | 17 · $3.5M |
| 2025 | 12 | 0 | 4 · $598K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| MRNA | Option / conversion M | September 4, 2026 | September 8, 2026 | 4d | 11,797 | — | — | derivative | Form 4 ↗ | |
| MRNA | Sell F | September 4, 2026 | September 8, 2026 | 4d | 5,704 | $149 | $849K | Form 4 ↗ | ||
| MRNA | Option / conversion M | September 4, 2026 | September 8, 2026 | 4d | 11,797 | — | — | Form 4 ↗ | ||
| MRNA | Option / conversion M | September 1, 2026 | September 3, 2026 | 2d | 2,166 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| MRNA | Option / conversion M | September 1, 2026 | September 3, 2026 | 2d | 3,471 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| MRNA | Sell F | September 1, 2026 | September 3, 2026 | 2d | 1,048 | $140 | $147K | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Option / conversion M | September 1, 2026 | September 3, 2026 | 2d | 2,166 | — | — | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Sell S | September 1, 2026 | September 3, 2026 | 2d | 3,471 | $140 | $486K | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Option / conversion M | September 1, 2026 | September 3, 2026 | 2d | 3,471 | $31 | $107K | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Option / conversion M | August 28, 2026 | August 31, 2026 | 3d | 329 | — | — | derivative | Form 4 ↗ | |
| MRNA | Option / conversion M | August 27, 2026 | August 31, 2026 | 4d | 774 | — | — | derivative | Form 4 ↗ | |
| MRNA | Sell F | August 28, 2026 | August 31, 2026 | 3d | 160 | $143 | $23K | Form 4 ↗ | ||
| MRNA | Option / conversion M | August 28, 2026 | August 31, 2026 | 3d | 329 | — | — | Form 4 ↗ | ||
| MRNA | Sell F | August 27, 2026 | August 31, 2026 | 4d | 375 | $150 | $56K | Form 4 ↗ | ||
| MRNA | Option / conversion M | August 27, 2026 | August 31, 2026 | 4d | 774 | — | — | Form 4 ↗ | ||
| MRNA | Option / conversion M | June 5, 2026 | June 8, 2026 | 3d | 11,798 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| MRNA | Option / conversion M | June 4, 2026 | June 8, 2026 | 4d | 3,471 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| MRNA | Sell F | June 5, 2026 | June 8, 2026 | 3d | 5,705 | $52 | $294K | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Option / conversion M | June 5, 2026 | June 8, 2026 | 3d | 11,798 | — | — | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Sell S | June 4, 2026 | June 8, 2026 | 4d | 3,471 | $50 | $174K | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Option / conversion M | June 4, 2026 | June 8, 2026 | 4d | 3,471 | $31 | $107K | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Option / conversion M | June 1, 2026 | June 3, 2026 | 2d | 2,165 | — | — | derivative | Form 4 ↗ | |
| MRNA | Sell F | June 1, 2026 | June 3, 2026 | 2d | 1,047 | $47 | $49K | Form 4 ↗ | ||
| MRNA | Option / conversion M | June 1, 2026 | June 3, 2026 | 2d | 2,165 | — | — | Form 4 ↗ | ||
| MRNA | Option / conversion M | May 28, 2026 | May 29, 2026 | 1d | 328 | — | — | derivative | Form 4 ↗ | |
| MRNA | Option / conversion M | May 27, 2026 | May 29, 2026 | 2d | 773 | — | — | derivative | Form 4 ↗ | |
| MRNA | Sell F | May 28, 2026 | May 29, 2026 | 1d | 159 | $48 | $7,570 | Form 4 ↗ | ||
| MRNA | Option / conversion M | May 28, 2026 | May 29, 2026 | 1d | 328 | — | — | Form 4 ↗ | ||
| MRNA | Sell F | May 27, 2026 | May 29, 2026 | 2d | 374 | $47 | $18K | Form 4 ↗ | ||
| MRNA | Option / conversion M | May 27, 2026 | May 29, 2026 | 2d | 773 | — | — | Form 4 ↗ | ||
| MRNA | Option / conversion M | March 5, 2026 | March 6, 2026 | 1d | 11,797 | — | — | derivative | Form 4 ↗ | |
| MRNA | Sell F | March 5, 2026 | March 6, 2026 | 1d | 5,704 | $58 | $330K | Form 4 ↗ | ||
| MRNA | Option / conversion M | March 5, 2026 | March 6, 2026 | 1d | 11,797 | — | — | Form 4 ↗ | ||
| MRNA | Option / conversion M | March 2, 2026 | March 3, 2026 | 1d | 13,885 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| MRNA | Other A | March 1, 2026 | March 3, 2026 | 2d | 38,553 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| MRNA | Other A | March 1, 2026 | March 3, 2026 | 2d | 29,275 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| MRNA | Option / conversion M | February 27, 2026 | March 3, 2026 | 4d | 8,663 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| MRNA | Option / conversion M | February 27, 2026 | March 3, 2026 | 4d | 774 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| MRNA | Option / conversion M | February 27, 2026 | March 3, 2026 | 4d | 329 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| MRNA | Option / conversion M | February 27, 2026 | March 3, 2026 | 4d | 233 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| MRNA | Sell S | March 2, 2026 | March 3, 2026 | 1d | 13,885 | $52 | $726K | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Option / conversion M | March 2, 2026 | March 3, 2026 | 1d | 13,885 | $31 | $430K | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Sell F | February 27, 2026 | March 3, 2026 | 4d | 4,189 | $52 | $217K | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Option / conversion M | February 27, 2026 | March 3, 2026 | 4d | 8,663 | — | — | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Sell F | February 27, 2026 | March 3, 2026 | 4d | 375 | $52 | $19K | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Option / conversion M | February 27, 2026 | March 3, 2026 | 4d | 774 | — | — | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Sell F | February 27, 2026 | March 3, 2026 | 4d | 160 | $52 | $8,274 | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Option / conversion M | February 27, 2026 | March 3, 2026 | 4d | 329 | — | — | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Sell F | February 27, 2026 | March 3, 2026 | 4d | 113 | $52 | $5,843 | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Option / conversion M | February 27, 2026 | March 3, 2026 | 4d | 233 | — | — | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Sell F | February 11, 2026 | February 13, 2026 | 2d | 1,334 | $42 | $56K | Form 4 ↗ | ||
| MRNA | Other A | February 11, 2026 | February 13, 2026 | 2d | 2,630 | — | — | Form 4 ↗ | ||
| MRNA | Option / conversion M | December 5, 2025 | December 8, 2025 | 3d | 47,190 | — | — | derivative | Form 4 ↗ | |
| MRNA | Sell F | December 5, 2025 | December 8, 2025 | 3d | 22,817 | $25 | $582K | Form 4 ↗ | ||
| MRNA | Option / conversion M | December 5, 2025 | December 8, 2025 | 3d | 47,190 | — | — | Form 4 ↗ | ||
| MRNA | Option / conversion M | December 1, 2025 | December 2, 2025 | 1d | 233 | — | — | derivative | Form 4 ↗ | |
| MRNA | Sell F | December 1, 2025 | December 2, 2025 | 1d | 113 | $26 | $2,936 | Form 4 ↗ | ||
| MRNA | Option / conversion M | December 1, 2025 | December 2, 2025 | 1d | 233 | — | — | Form 4 ↗ | ||
| MRNA | Option / conversion M | November 28, 2025 | December 1, 2025 | 3d | 329 | — | — | derivative | Form 4 ↗ | |
| MRNA | Option / conversion M | November 26, 2025 | December 1, 2025 | 5d | 773 | — | — | latederivative | Form 4 ↗ | |
| MRNA | Sell F | November 28, 2025 | December 1, 2025 | 3d | 160 | $25 | $4,002 | Form 4 ↗ | ||
| MRNA | Option / conversion M | November 28, 2025 | December 1, 2025 | 3d | 329 | — | — | Form 4 ↗ | ||
| MRNA | Sell F | November 26, 2025 | December 1, 2025 | 5d | 374 | $25 | $9,257 | late | Form 4 ↗ | |
| MRNA | Option / conversion M | November 26, 2025 | December 1, 2025 | 5d | 773 | — | — | late | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| September 8, 2026 | Form 4 | 0001682852-26-000169 | 3 | published | EDGAR ↗ |
| September 3, 2026 | Form 4 | 0001682852-26-000167 | 6 | published | EDGAR ↗ |
| August 31, 2026 | Form 4 | 0001682852-26-000157 | 6 | published | EDGAR ↗ |
| June 8, 2026 | Form 4 | 0001682852-26-000119 | 6 | published | EDGAR ↗ |
| June 3, 2026 | Form 4 | 0001682852-26-000113 | 3 | published | EDGAR ↗ |
| May 29, 2026 | Form 4 | 0001682852-26-000107 | 6 | published | EDGAR ↗ |
| March 6, 2026 | Form 4 | 0001682852-26-000051 | 3 | published | EDGAR ↗ |
| March 3, 2026 | Form 4 | 0001682852-26-000040 | 17 | published | EDGAR ↗ |
| February 13, 2026 | Form 4 | 0001682852-26-000021 | 2 | published | EDGAR ↗ |
| December 8, 2025 | Form 4 | 0001682852-25-000088 | 3 | published | EDGAR ↗ |
| December 2, 2025 | Form 4 | 0001682852-25-000086 | 3 | published | EDGAR ↗ |
| December 1, 2025 | Form 4 | 0001682852-25-000080 | 6 | published | EDGAR ↗ |
Other insiders at Moderna, Inc.
- Hoge Stephen President 76 rows
- Mock James M Chief Financial Officer 68 rows
- Bancel Stephane Chief Executive Officer 15 rows
- AFEYAN NOUBAR Director 7 rows
- Hussain Abbas Director 7 rows
- Horning Sandra Director 6 rows
- McDonnell Michael R. Director 6 rows
- NABEL ELIZABETH G Director 5 rows
- Nader Francois Director 4 rows
- Rubenstein David M. Director 4 rows
Everyone on file, with contracts and lobbying under the company's name: Moderna, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 12 | 64 | December 1, 2025 | September 8, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.